Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析

◆英語タイトル:Vertex Pharmaceuticals Inc (VRTX) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1332
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Vertex Pharmaceuticals Inc (VRTX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on influenza, cancer, neurological diseases and pain. Vertex has R&D centers and commercial offices in North America, South America, Europe and Australia. The company offers its products in the US, Europe, Australia and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Inc Key Recent Developments

Mar 27,2020: GN MEDI antibacterial spray launched to end covid-19 crisis and solve the shortage of masks
Mar 27,2020: Vertex confirms supply chain continuity and business outlook for its cystic fibrosis medicines and provides initial update on development programs
Mar 17,2020: Sickle Cell Anemia Industry Outlook to 2026 Featuring CRISPR Therapeutics, Global Blood Therapeutics, Novartis, Pfizer, and Vertex Pharmaceuticals
Mar 13,2020: The Vertex Foundation donates $500,000 to partners healthCare to support COVID-19 outbreak response

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Vertex Pharmaceuticals Inc – Key Facts
Vertex Pharmaceuticals Inc – Key Employees
Vertex Pharmaceuticals Inc – Key Employee Biographies
Vertex Pharmaceuticals Inc – Major Products and Services
Vertex Pharmaceuticals Inc – History
Vertex Pharmaceuticals Inc – Company Statement
Vertex Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Vertex Pharmaceuticals Inc – Business Description
Business Segment: Pharmaceuticals
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Others
Performance
Geographical Segment: United States
Performance
R&D Overview
Vertex Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Vertex Pharmaceuticals Inc – Strengths
Vertex Pharmaceuticals Inc – Weaknesses
Vertex Pharmaceuticals Inc – Opportunities
Vertex Pharmaceuticals Inc – Threats
Vertex Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Vertex Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 27, 2020: GN MEDI antibacterial spray launched to end covid-19 crisis and solve the shortage of masks
Mar 27, 2020: Vertex confirms supply chain continuity and business outlook for its cystic fibrosis medicines and provides initial update on development programs
Mar 13, 2020: The Vertex Foundation donates $500,000 to partners healthCare to support COVID-19 outbreak response
Mar 09, 2020: Vertex confirms supply chain continuity and 2020 business outlook
Jan 30, 2020: Vertex reports full-year and fourth-quarter 2019 financial results
Oct 30, 2019: Vertex reports third-quarter 2019 financial results
Oct 24, 2019: NHS England concludes wide-ranging deal for cystic fibrosis drugs
Oct 24, 2019: Access to Orkambi and Symkevi agreed in England
Oct 01, 2019: Vertex appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer
Sep 12, 2019: Health Secretary welcomes cystic fibrosis drug pricing agreement
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Vertex Pharmaceuticals Inc, Key Facts
Vertex Pharmaceuticals Inc, Key Employees
Vertex Pharmaceuticals Inc, Key Employee Biographies
Vertex Pharmaceuticals Inc, Major Products and Services
Vertex Pharmaceuticals Inc, History
Vertex Pharmaceuticals Inc, Subsidiaries
Vertex Pharmaceuticals Inc, Key Competitors
Vertex Pharmaceuticals Inc, Ratios based on current share price
Vertex Pharmaceuticals Inc, Annual Ratios
Vertex Pharmaceuticals Inc, Annual Ratios (Cont...1)
Vertex Pharmaceuticals Inc, Annual Ratios (Cont...2)
Vertex Pharmaceuticals Inc, Interim Ratios
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Vertex Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Vertex Pharmaceuticals Inc, Performance Chart (2015 - 2019)
Vertex Pharmaceuticals Inc, Ratio Charts
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Verathon Inc:企業の戦略的SWOT分析
    Verathon Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • GeoVax Labs Inc (GOVX)-製薬・医療分野:企業M&A・提携分析
    Summary GeoVax Labs Inc (GeoVax) is a clinical-stage biotechnology company, which develops human vaccines for diseases caused by HIV, cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company’s vaccine development programs focus o …
  • Johnson Controls International Plc (JCI):電力:M&Aディール及び事業提携情報
    Summary Johnson Controls International Plc (Johnson Controls) is a diversified technology and multi industrial company. It creates intelligent buildings, integrated infrastructure, efficient energy solutions, and next generation transportation systems. The company provides HVAC equipment, HVAC contr …
  • UltraTech Cement Ltd:企業の戦略・SWOT・財務情報
    UltraTech Cement Ltd - Strategy, SWOT and Corporate Finance Report Summary UltraTech Cement Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Oriola-KD Oyj (OKDBV):企業の財務・戦略的SWOT分析
    Oriola-KD Oyj (OKDBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sequana Medical AG:医療機器:M&Aディール及び事業提携情報
    Summary Sequana Medical AG (Sequana Medical), formerly NovaShunt AG, is a commercial stage medical device company that offers automated implantable pump systems to monitor fluid balance within the body. The company designs, develops and commercializes alfapump, a fully implantable, programmable, tra …
  • Bemis Company Inc (BMS):企業の財務・戦略的SWOT分析
    Bemis Company Inc (BMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • J. Front Retailing Co Ltd
    J. Front Retailing Co Ltd - Strategy, SWOT and Corporate Finance Report Summary J. Front Retailing Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • SMU S.A. (SMU):企業の財務・戦略的SWOT分析
    SMU S.A. (SMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Arix Bioscience PLC:企業のM&A・事業提携・投資動向
    Arix Bioscience PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Arix Bioscience PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • WESCO International, Inc.:企業の戦略・SWOT・財務情報
    WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report Summary WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Qisda Corporation:戦略・SWOT・企業財務分析
    Qisda Corporation - Strategy, SWOT and Corporate Finance Report Summary Qisda Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Majesco:企業の戦略・SWOT・財務情報
    Majesco - Strategy, SWOT and Corporate Finance Report Summary Majesco - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Helix Energy Solutions Group, Inc.:企業の戦略・SWOT・財務情報
    Helix Energy Solutions Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Helix Energy Solutions Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Pharm-Olam International Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Pharm-Olam International Ltd (Pharm-Olam) is a contract research organization (CRO) which offers clinical research services to the pharmaceutical, biotechnology and medical device industries. The organization's service offerings include medical writing, monitoring, regulatory and ethics subm …
  • Mologen AG:企業のM&A・事業提携・投資動向
    Mologen AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mologen AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析
    Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析
    H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Exact Sciences Corp (EXAS):企業の財務・戦略的SWOT分析
    Exact Sciences Corp (EXAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary NGM Biopharmaceuticals Inc (NGM Bio) is a clinical stage biopharmaceutical company which focuses on the development of drug discovery platform to generate biologic drug candidates to treat cardio-metabolic, immuno-oncology and liver diseases. Its product pipeline includes NGM282, NGM386, NGM …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆